Chemotherapy with Taxotere (docetaxel) might not be considered because the side effects are misunderstood. Individual experiences and side effects differ widely from one man to another. n Generally, chemotherapy is not as toxic as we think. Even if a patient feels that his chemotherapy is causing more grief than relief, it can be discontinued; there [...]
According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side effect results from damage to the peripheral nerves and is felt by the man as weakness, numbness and pain most [...]
Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]
Clinical trials for treatment of men with advanced prostate cancer often don’t include men who are considered very elderly (aged over 80 years). So, even if we know that a treatment is tolerable and effective in the average man, we can not assume that it would also be in the very elderly, especially in reference [...]
During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]